What is ETON's P/E ratio?

ETON PHARMACEUTICALS INC (ETON) currently trades at a P/E ratio of 442.23.

ETON PHARMACEUTICALS INC reports a Return on Equity (ROE) of -4.82%.

What is ETON's dividend yield?

ETON PHARMACEUTICALS INC offers a dividend yield of 0.00%.

What is ETON's Quality Score?

Our AI rates ETON's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ETON?

Our AI Timing Score for ETON is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ETON belong to?

ETON PHARMACEUTICALS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

ETON (NASDAQ) Stock Analysis | ETON PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ETON AI Analysis Summary

Our AI summary for ETON: ETON PHARMACEUTICALS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 442.23, ROE of -4.82%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ETON

ETON PHARMACEUTICALS INC

USD 46.42

-2.61 (-5.32%) Day Change

Watchlist Portfolio Compare Chart

442.23

P/E

1.00

D/E

-4.8%

ROE

-1.5%

ROA

0.00%

Div Yield

5.76

PEG

ETON PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 46.42 Price -2.61 (-5.32%) Day Change	NEWS SCORE: 97

ETON, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	97
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	46.42
PBV / Sector	43.87 / 3.22
Earning Per Share	-0.05

PE / Sector	442.23 / 29.79
PEG or PE/Growth / Sector	5.76 / 0.13
Average 1M Daily Value	22.26 M GREAT
Average 1W Daily Value	28.21 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1.70 / 15.21
NPM Average (%) / Sector	-12.53 / -10.83
NPM Change Average (%) / Sector	6.62 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-1.51 / 8.15
ROA Average (%) / Sector	-10.10 / 2.87
ROA Change Average (%) / Sector	-22.96 / 112.70
ROE (%) / Sector	-4.82 / -1.02
ROE Average (%) / Sector	-22.62 / 8.35
ROE Change Average (%) / Sector	1.84 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 07:59:48
Symbol	ETON
Name	ETON PHARMACEUTICALS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	27.39 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,343.05 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278

Phone: 847 787 7361

Website: https://www.etonpharma.com

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.